Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gains from Investment Securities (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 10 years of Gains from Investment Securities data on record, last reported at -$886000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 42.9% year-over-year to -$886000.0; the TTM value through Dec 2025 reached -$1.5 million, down 142.9%, while the annual FY2025 figure was -$157000.0, 74.68% up from the prior year.
  • Gains from Investment Securities reached -$886000.0 in Q4 2025 per VRDN's latest filing, down from -$620000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $75000.0 in Q4 2021 and bottomed at -$886000.0 in Q4 2025.
  • Average Gains from Investment Securities over 4 years is -$167333.3, with a median of -$8000.0 recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 105.81% in 2021, down 183.72% in 2021.
  • A 4-year view of Gains from Investment Securities shows it stood at $75000.0 in 2021, then crashed by 58.67% to $31000.0 in 2023, then tumbled by 2100.0% to -$620000.0 in 2024, then tumbled by 42.9% to -$886000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$886000.0 in Q4 2025, -$620000.0 in Q4 2024, and $31000.0 in Q3 2023.